Pop Test Cortisol acquires chemotherapy sensitizer Org34517 from Merck & Co.
Pre-clinical trials demonstrate significant outcomes -- Breast Cancer growth slowed and reversed
CLIFFSIDE PARK, N.J. & KURUME, Japan--(BUSINESS WIRE)--Oct 25, 2011 - Pop Test Cortisol LLC, under the umbrella of the POP Test companies, today announced pre-clinical trials in which the company has successfully demonstrated the efficacy of a chemotherapy sensitizer for “triple negative” breast cancer. These are the most difficult to treat breast cancers, testing negative for estrogen-receptor, progesterone-receptor and her-2/neu and are resistant to chemotherapy.
Org34517, first developed as a therapy for major depressive disorder, was first formulated by Organon. In 2007, Org34517 was acquired by Schering-Plough, then Merck, and ultimately acquired by Pop Test Cortisol LLC in December of 2010.
For neuropsychiatric and other conditions, the drug is to be combined with the Pop Test cortisol rapid response saliva diagnostic to determine the patients with high blood and cortisol levels who are most likely to benefit from using the drug. Org34517 has already completed phase 2 clinical studies for such neuropsychiatric use with proven human safety and efficacy. Upon further development and investigation, Dr. Neil Theise, Medical Director for the Pop Test companies and Professor of Pathology and Medicine, internationally known as a thought leader in chronic liver diseases, liver cancer, and adult stem cell research, recognized that the drug could be used for wide ranging indications beyond the psychotic major depression for which it was first created.
Dr. Theise's vision is that glucocorticoid receptor blockade by Org34517 is a way of changing some human cancers, such as some breast, liver and ovarian malignancies, from chemotherapy resistant to chemosensitive. With the collaborative assistance of Dr. Hirohisa Yano, Chairman of Pathology of Kurume University School of Medicine, Kurume, Japan, additional studies are underway. Pop Test CEO Randi Altschul, commenting on the development of Org34517, said “We are tremendously optimistic about the potential for this game-changing drug in the lives of people everywhere. We are in talks with major pharmaceutical companies worldwide to partner in bringing this drug through the FDA development process so that it can be commercially available to those who need it.”
For additional information on Pop Test products, visit us at www.DiabetesPopTest.com, call 1-201-943-3770.
About Pop Test Cortisol LLC
Pop Test Cortisol LLC is part of the Pop Test group of companies. Pop Test was founded in 2008 with the creation of the saliva based diabetes testing platform planned for launch with Walmart in 2012. The company has since developed a series of diagnostic platforms including the saliva Pop Test devices and lateral flow diagnostics for biological and agricultural applications. Pop Test has put together a world class team for it's expansion into drug development resulting in rapid discovery and expansion of indications. Currently, the Pop Test Companies are seeking relationships with major pharmaceutical companies to commercialize our breakthroughs.
About Dr. Neil Theise
Neil Theise, MD is a diagnostic pathologist and adult stem cell researcher in New York City where he is Professor of Pathology and of Medicine at a major New York college of medicine. His research revised understandings of human liver microanatomy which, in turn, led directly to identification of human liver stem cell niches. Also considered a pioneer of multi-organ, adult, stem cell plasticity Dr. Theise has published on that topic in the top scientific and medical journals such as Cell, Science, Nature, and the Lancet. Additionally, Dr. Theise is an international authority on human liver and biliary tract malignancy, recently serving as co-editor and co-author of the World Health Organization's newest edition of the “Diagnostic Manual of Tumors of the Digestive Tract.”
About Dr. Hirohisa Yano
Hirohisa Yano is Professor and Chairman of the Department of Pathology, Kurume University School of Medicine (Japan). He received his M.D. degree from Kurume University School of Medicine in 1983 and his Ph.D. degree from Kurume University in 1987. From 1987-1989, Yano was a Research Fellow at the Department of Pathology, Beth Israel Hospital in Boston, Massachusetts, USA. In 1989, he returned to Kurume University School of Medicine where he became a Fellow at the Department of Pathology (1989-2002) before he joined the faculty as Assistant Professor (1991-2002). He was promoted to Associate Professor in 2002 and appointed Professor and Chairman of the Department of Pathology in 2007.
Contact: Pop Test Companies
Randi Altschul, 201-943-3770
Posted: October 2011